

Q2FY2012 Review
Sector: Pharmaceuticals
BSE Sensex: 17,255

Dr Reddy's Laboratories

Maintain SELL
CMP Rs1,580
TP Rs1,442

25 October 2011

Margins disappoints, in spite of strong revenue growth

DRL reported strong revenue growth driven by US, Russia and PSAI segments. The growth on the low-margin PSAI front was a positive surprise. However, the high-margin domestic formulation segment continues to grow below the industry average. Further the EBIT margins, in spite of strong revenue growth, continue to disappoint on back of higher raw-material and employee cost, coupled with marketing expenses in Russia/CIS region.

We value DRL on a SOTP basis with a target price of Rs1,442, valuing the base business now at Rs1,379 (18x one year forward recurring earnings) and Rs63/share for P-IV/ limited competition opportunities. We maintain our SELL rating on the stock.

PSAI segment surprises on the positive side

DRL reported revenue of Rs22.7bn up 21.3% YoY which was ahead of our estimates driven by US, Russia and PSAI segments. US formulation segment continued with the strong performance clocking 42.4% YoY growth on back of product launches (Allegra D-24 OTC and generic Arixtra) and improvement of market share in existing products. Further, Russia & CIS segments also clocked robust growth of 22.9% YoY. The surprise came from the PSAI segment which grew by 28.5% YoY driven by new product launches in Europe. However, India formulation segment continues to disappoint with below industry average growth rate.

Pressure on EBIT still persists

DRL reported adjusted EBIT of 15.3%, in spite of stellar growth from the US business coupled with the surprise from the PSAI segment, impacted by higher raw-material cost and SG&A expenses. The increase in SG&A expenses continued for the second consecutive quarter on account of higher employee cost, marketing expenses in Russia and overhead cost at the acquired GSK facility.

VALUATIONS AND RECOMMENDATION

We value DRL on a SOTP basis with a target price of Rs1,442, valuing the base business now at Rs1,379 (18x one year forward recurring earnings) and Rs63/share for P-IV/ limited competition opportunities. The stock is trading at 24.1x FY12E and 19.7x FY13E recurring earnings. We maintain our SELL rating on the stock.

KEY FINANCIALS (Rs mn)

	FY09	FY10	FY11	FY12E	FY13E
Recurring Sales	60,979	67,046	69,974	80,704	92,620
YoY Gr. (%)	34.2	9.9	4.4	15.3	14.8
Recurring EBIT	5,197	8,296	9,721	12,464	15,450
Recurring EBIT (%)	8.5	12.4	13.9	15.4	16.7
Recurring Net Profit	1,242	9,728	8,714	11,103	13,586
YoY Gr.(%)	(54.3)	683.1	(10.4)	27.4	22.4

KEY RATIOS

Dil. EPS (Rs)	-	6.3	65.3	93.7	101.1
ROCE (%)	(3.4)	2.4	14.4	18.3	17.6
RoE (%)	13.4	27.3	24.8	30.0	25.6
PER (x)	-	250.5	24.2	16.9	15.6
EV/ Net Sales (x)	4.4	4.0	3.8	3.3	2.8
EV/EBIDTA (x)	52.0	32.0	27.4	21.5	17.0

Sushant Dalmia, CFA

sushant.dalmia@pinc.co.in
+91-22-6618 6462

Poonam Sanghavi

poonam.sanghavi@pinc.co.in
+91-22-6618 6709

QUARTERLY SNAPSHOT (Rs mn)

	Quarter Ended		
	Mar-11	June-11	Sept-11
Net sales	20,170	19,784	22,679
YoY Gr. (%)	22.8	17.5	21.3
Op. Profit	2,318	2,551	3,345
OPM (%)	13.1	13.2	15.3
Adj.Net Profit	3,343	2,627	3,078
YoY Gr. (%)	57.8	25.3	7.4


STOCK DATA

Market cap	Rs267bn
Book Value per share	Rs351
Shares O/S (F.V. Rs5)	169mn
Free Float	74.4%
Avg. Trade Value (6 months)	Rs560mn
52 week High/Low	Rs1,855/1,387
Bloomberg Code	DRRD IN
Reuters Code	REDY.BO

PERFORMANCE (%)

	1M	3M	12M
Absolute	6.3	0.1	(4.4)
Relative	(0.5)	7.4	12.1

RELATIVE PERFORMANCE



Key call takeaways

- 1) US: a) DRL expects revenue growth in H2FY12 to be better than H1FY12 on back of product launches and improvement in market share in existing products b) The company has garnered market share of 32% in Tacrolimus, 20% each in Lansoprazole and Omeprazole and 10% in generic Arixtra c) Two plants underwent successful USFDA inspection including Vizag.
- 2) Gross margins for global generic business stood at 63% down by 50-60bps YoY on back of higher raw material cost while PSAI segment gross margins came in at 28%, up 600bps YoY driven by new product launches.
- 3) Domestic: a) September month IMS growth for DRL stood at 14%; this is in-line with company's expectation. b) The company expects recovery in H2FY12.
- 4) PSAI a) Strong growth on back of new product launches in Europe b) DRL expects the growth momentum on the revenue front to continue.
- 5) Europe a) Germany tender business continues to face pricing pressure.
- 6) Withdrawal of DEPB scheme to impact profitability by 100-120mn per quarter.
- 7) Capex of USD73mn in H1FY12.
- 8) Tax rate for FY12 to be in range of 18-20%.
- 9) R&D spend in H2FY12 to higher than H1FY12.
- 10) Guidance of USD2.7bn on the revenue front remains intact.

Exhibit 1 - Earnings Summary (Rs mn)

Year to Mar 31	Q2FY11	Q2FY12	% Ch YoY	Q1FY12	% Ch QoQ	H1FY11	H1FY12	% Ch YoY	PINC Comments
Recurring revenues	17,943	21,820	21.6	19,256	13.3	34,110	41,076	20.4	Driven by US, Russia and PSAI segment.
Unique products	761	859	12.8	528	62.7	1,425	1,387	(2.7)	
Total revenues	18,704	22,679	21.3	19,784	14.6	35,535	42,463	19.5	
Cost of revenues	8,718	10,473	20.1	9,228	13.5	16,635	19,701	18.4	
Gross Profit	9,986	12,206	22.2	10,556	15.6	18,900	22,762	20.4	Margins expand by 43 bps YoY.
<i>Gross Margin (%)</i>	<i>53.4</i>	<i>53.8</i>	<i>43 bps</i>	<i>53.4</i>	<i>46 bps</i>	<i>53.2</i>	<i>53.6</i>	<i>42 bps</i>	
SG&A Expenses	5,392	6,827	26.6	6,351	7.5	10,586	13,178	24.5	Higher freight costs, Annual increments across businesses, increased marketing spend in Russia and overhead costs at the acquired GSK facility.
<i>as a % of recurring sales</i>	<i>30.1</i>	<i>31.3</i>	<i>124 bps</i>	<i>33.0</i>	<i>(169) bps</i>	<i>31.0</i>	<i>32.1</i>	<i>105 bps</i>	
R&D Expenses	1,270	1,459	14.9	1,197	21.9	2,263	2,656	17.4	
<i>as a % of recurring sales</i>	<i>7.1</i>	<i>6.7</i>	<i>(39) bps</i>	<i>6.2</i>	<i>47 bps</i>	<i>6.6</i>	<i>6.5</i>	<i>(17) bps</i>	
Amortization Expenses	317	389	22.7	405	(4.0)	605	794	31.2	
Other operating expense/(income)	(218)	(215)	nm	(186)	nm	(404)	(401)	nm	
Total Operating Expenses	6,761	8,460	25.1	7,767	8.9	13,050	16,227	24.3	
EBIT	3,225	3,746	16.2	2,789	34.3	5,850	6,535	11.7	
<i>EBIT Margin (%)</i>	<i>17.2</i>	<i>16.5</i>	<i>(72) bps</i>	<i>14.1</i>	<i>242 bps</i>	<i>16.5</i>	<i>15.4</i>	<i>(107) bps</i>	
Recurring EBIT	2,743	3,345	22.0	2,551	31.1	4,932	5,991	21.5	
<i>Recurring EBIT (%)</i>	<i>15.3</i>	<i>15.3</i>	<i>4 bps</i>	<i>13.2</i>	<i>208 bps</i>	<i>14.5</i>	<i>14.6</i>	<i>12 bps</i>	Adjusted for VRS expenses.
Net interest expenses/(Income)	35.0	50.0	42.9	46.0	8.7	212.0	96.0	nm	Includes net forex gain of Rs151mn and profit on sale of investments of Rs25mn.
Equity in Loss of Affiliates	(3)	(13)	nm	(4)	nm	(8)	(17)	nm	
Other Income / (Expenses)	-	-	-	-	-	-	-	-	
PBT	3,193	3,709	16.2	2,747	35.0	5,646	6,456	14.3	
Tax	327	631	93.0	120	425.8	684	751	9.8	
<i>Effective tax rate</i>	<i>10.2</i>	<i>17.0</i>	<i>677 bps</i>	<i>4.4</i>	<i>1,264 bps</i>	<i>12.1</i>	<i>11.6</i>	-	
Minority Interest	-	-	nm	-	nm	-	-	nm	
Reported Net Income	2,866	3,078	7.4	2,627	17.2	4,962	5,705	15.0	
One off expenses/ (Income)	-	-	nm	-	nm	-	-	nm	
Recurring Net Income	2,866	3,078	7.4	2,627	17.2	4,962	5,705	15.0	Adjusting for one time expenses and tax normalizing.


Source: Company, PINC Research

Exhibit 2 - Revenue Break-up (Rs mn)

Year to Mar 31	Q2FY11	Q2FY12	% Ch YoY	Q1FY12	% Ch QoQ	H1FY11	H1FY12	% Ch YoY	PINC Comments
Generics	6,782	8,404	23.9	7,673	9.5	12,616	16,077	27.4	
North America	4,416	6,287	42.4	5,756	9.2	8,313	12,043	44.9	Led by new product launches (Allegra D-24 OTC and generic Arixtra) including limited competition products and market share improvement.
Europe	2,366	2,117	(10.5)	1,917	10.4	4,303	4,034	(6.3)	De-growth on back of price erosions in Germany.
Branded Formulations	6,885	7,732	12.3	6,751	14.5	12,969	14,483	11.7	
India	3,160	3,459	9.5	2,936	17.8	5,938	6,395	7.7	
Russia & Other CIS	2,751	3,380	22.9	3,018	12.0	5,303	6,398	20.6	Driven by OTC segment and prescription sales growth.
RoW	974	893	(8.3)	797	12.0	1,728	1,690	(2.2)	
PSAI	4,617	5,933	28.5	4,832	22.8	9,116	10,765	18.1	Driven by improvement in the customer order status of the contract manufacturing segment.
North America	814	1,068	31.2	842	26.8	1,651	1,910	15.7	
Europe	1,551	2,303	48.5	1,693	36.0	3,106	3,996	28.7	Led by new product launches.
India	653	752	15.2	662	13.6	1,286	1,414	10.0	
RoW	1,599	1,810	13.2	1,635	10.7	3,073	3,445	12.1	
Others	420	610	45.2	528	15.5	835	1,138	36.3	
Total Revenues	18,704	22,679	21.3	19,784	14.6	35,535	42,463	19.5	


Source: PINC Research, Company

Exhibit 3 - Revenue Classification (%)




Source: PINC Research, Company

Exhibit 4 - Key Expenses and EBITDA




Source: PINC Research, Company

Exhibit 5 - Indexing of Key Financials




Source: PINC Research, Company

Exhibit 6 - Indexing of Revenue Mix




Source: PINC Research, Company

Exhibit 7 - Base Business and One time Opportunity



Source: PINC Research, Company

Exhibit 8 - US Recurring Sales Performance



Source: PINC Research, Company

Year Ended March (Figures in Rs mn based in IFRS)

Income Statement	FY09	FY10	FY11	FY12E	FY13E
Recurring Net Sales	60,979	67,046	69,974	80,704	92,620
<i>Growth (%)</i>	<i>34.2</i>	<i>9.9</i>	<i>4.4</i>	<i>15.3</i>	<i>14.8</i>
Unique Opportunities	8,461	3,230	4,719	10,388	9,911
Reported Net Sales	69,440	70,276	74,693	91,093	102,530
<i>Growth (%)</i>	<i>38.9</i>	<i>1.2</i>	<i>6.3</i>	<i>22.0</i>	<i>12.6</i>
Recurring EBIT	5,197	8,296	9,721	12,464	15,450
<i>Growth (%)</i>	<i>30.2</i>	<i>59.6</i>	<i>17.2</i>	<i>28.2</i>	<i>24.0</i>
Other Income	1,186	3	189	32	40
Equity loss of affiliates	24	48	3	-	-
Reported EBIT	(4,065)	2,052	12,444	18,429	19,897
Tax Provision	(1,173)	(985)	(1,403)	(2,580)	(2,786)
Reported Net Profit*	(5,238)	1,067	11,041	15,849	17,112
E/o income/(loss)	11,218	10,513	-	-	-
Recurring Net Profit	1,242	9,728	8,714	11,103	13,586
<i>Growth (%)</i>	<i>(54.3)</i>	<i>683.1</i>	<i>(10.4)</i>	<i>27.4</i>	<i>22.4</i>
Reported EPS (Rs) *	-	6.3	65.3	93.7	101.1
<i>EPS Growth (%)</i>	<i>-</i>	<i>-</i>	<i>-</i>	<i>43.6</i>	<i>8.0</i>


* including unique opportunities

Cash Flow Statement	FY09	FY10	FY11	FY12E	FY13E
Net Income	(5,238)	1,067	11,041	15,849	17,112
Depreciation	3,814	4,160	-	-	-
Total Tax Paid	(1,619)	(1,846)	-	-	-
Chg in working capital	(8,459)	(1,572)	(11,236)	(2,373)	(3,544)
Other operating activities	15,790	11,238	5,991	(4,289)	(2,000)
Cash flow from oper (a)	4,288	13,047	5,796	9,188	11,567
Capital Expenditure	(4,680)	(4,222)	(8,456)	(7,900)	(4,900)
Chg in investments	4,294	(3,009)	3,567	-	-
Other investing activities	(3,086)	233	-	-	-
Cash flow from inv.(b)	(3,472)	(6,998)	(4,889)	(7,900)	(4,900)
Free cash flow (a+b)	816	6,049	907	1,288	6,667
Equity raised/(repaid)	5	17	256	-	-
Debt raised/(repaid)	(662)	(3,562)	(114)	-	-
Change in Minority Int	-	(80)	-	-	-
Dividend (incl. Tax)	(738)	(1,233)	(1,904)	(2,335)	(2,530)
Other financing activities	(1,246)	(203)	-	-	-
Cash flow from fin. (c)	(2,641)	(5,061)	(1,762)	(2,335)	(2,530)
Net chg in cash (a+b+c)	(1,825)	988	(855)	(1,047)	4,138

Balance Sheet	FY09	FY10	FY11	FY12E	FY13E
Equity Share Capital	842	844	846	846	846
Reserves & surplus	41,203	42,071	45,144	58,658	73,240
Shareholders' funds	42,045	42,915	45,990	59,504	74,086
Minorities interests	-	-	-	-	-
Total Debt	10,524	5,673	5,978	5,978	5,978
Capital Employed	52,569	48,588	51,968	65,482	80,064
Net fixed assets	43,061	36,432	44,888	52,788	57,688
Cash & Cash Eq.	5,596	6,584	5,729	4,682	8,819
Net Other current assets	8,320	7,982	3,060	9,722	15,266
Investments	262	310	313	313	313
Net Deferred tax Assets	(4,670)	(2,720)	(2,022)	(2,022)	(2,022)
Total Assets	52,569	48,588	51,968	65,482	80,064

Key Ratios	FY09	FY10	FY11	FY12E	FY13E
Recurring OPM (%)	8.5	12.4	13.9	15.4	16.7
Net Margin (%)	2.0	14.5	12.5	13.8	14.7
Div. Yield (%)	0.4	0.7	0.7	0.8	0.8
Net debt/Equity (x)	0.1	(0.1)	(0.0)	0.0	(0.0)
Net Working Capital (days)	43	40	14	38	53
ROCE (%)	(3.4)	2.4	14.4	18.3	17.6
RoE (%)	13.4	27.3	24.8	30.0	25.6
EV/Net Sales (x)	4.4	4.0	3.8	3.3	2.8
EV/EBITDA (x)	52.0	32.0	27.4	21.5	17.0
PER (x)	-	250.5	24.2	16.9	15.6
PCE (x)	96.8	23.8	30.7	24.1	19.7
Price/Book (x)	6.3	6.2	5.8	4.5	3.6

P/E Band



Key Assumption	FY10	FY11	FY12E	FY13E
Recurring business (% chng YoY)	9.9	4.4	15.3	14.8
One time opportunities (Rs m)	3,230	4,719	10,388	9,911
Gross Margins on base business (%)	50.7	53.4	53.7	53.8
OPMs (Ex-Onetime) (%)	12.4	13.9	15.4	16.7
Recurring EPS (Rs)	57.6	51.5	65.6	80.3
Recurring EPS growth (%)	680.8	(10.6)	27.4	22.4

T E A M

EQUITY DESK

Sadanand Raje	Head - Institutional Sales Technical Analyst	sadanand.raje@pinc.co.in	91-22-6618 6366
---------------	-------------------------------------------------	--------------------------	-----------------

RESEARCH

Vineet Hetamasaria, CFA	Head of Research, Auto, Cement	vineet.hetamasaria@pinc.co.in	91-22-6618 6388
Nikhil Deshpande	Auto, Auto Ancillary, Cement	nikhil.deshpande@pinc.co.in	91-22-6618 6339
Tasmai Merchant	Auto, Auto Ancillary, Cement	tasmai.merchant@pinc.co.in	91-22-6618 6377
Vinod Nair	Construction, Power, Capital Goods	vinod.nair@pinc.co.in	91-22-6618 6379
Ankit Babel	Capital Goods, Engineering	ankit.b@pinc.co.in	91-22-6618 6551
Hitul Gutka	Power	hitul.gutka@pinc.co.in	91-22-6618 6410
Subramaniam Yadav	Construction	subramaniam.yadav@pinc.co.in	91-22-6618 6371
Madhura Joshi	Power	madhura.joshi@pinc.co.in	91-22-6618 6395
Satish Mishra	Fertiliser, Natural Gas	satish.mishra@pinc.co.in	91-22-6618 6488
Urvashi Biyani	Fertiliser, Natural Gas	urvashi.biyani@pinc.co.in	91-22-6618 6334
Naveen Trivedi	FMCG	naveent@pinc.co.in	91-22-6618 6384
Rohit Kumar Anand	IT Services	rohit.anand@pinc.co.in	91-22-6618 6372
Namrata Sharma	Media	namrata.sharma@pinc.co.in	91-22-6618 6412
Sakshee Chhabra	Media	sakshee.chhabra@pinc.co.in	91-22-6618 6516
Bikash Bhalotia	Metals, Mining	bikash.bhalotia@pinc.co.in	91-22-6618 6387
Harleen Babber	Metals, Mining	harleen.babber@pinc.co.in	91-22-6618 6389
Dipti Vijaywargi	Metals, Mining	dipti.vijaywargi@pinc.co.in	91-22-6618 6393
Sushant Dalmia, CFA	Pharma	sushant.dalmia@pinc.co.in	91-22-6618 6462
Poonam Sanghavi	Pharma	poonam.sanghavi@pinc.co.in	91-22-6618 6709
Suman Memani	Real Estate, Mid caps	suman.memani@pinc.co.in	91-22-6618 6479
Abhishek Kumar	Real Estate, Mid caps	abhishek.kumar@pinc.co.in	91-22-6618 6398
C Krishnamurthy	Technical Analyst	krishnamurthy.c@pinc.co.in	91-22-6618 6747

SALES

Rajeev Gupta	Equities	rajeev.gupta@pinc.co.in	91-22-6618 6486
Ankur Varman	Equities	ankur.varman@pinc.co.in	91-22-6618 6380
Himanshu Varia	Equities	himanshu.varia@pinc.co.in	91-22-6618 6342
Shailesh Kadam	Derivatives	shaileshk@pinc.co.in	91-22-6618 6349
Ganesh Gokhale	Derivatives	ganeshg@pinc.co.in	91-22-6618 6347

DEALING

Mehul Desai	Head - Sales Trading	mehul.desai@pinc.co.in	91-22-6618 6303
Naresh Panjnani	Co-Head - Sales Trading	naresh.panjnani@pinc.co.in	91-22-6618 6333
Amar Margaje		amar.margaje@pinc.co.in	91-22-6618 6327
Ashok Savla		ashok.savla@pinc.co.in	91-22-6618 6321
Sajjid Lala		sajjid.lala@pinc.co.in	91-22-6618 6337
Raju Bhavsar		raju@pinc.co.in	91-22-6618 6322
Kinjal Mehta		kinjal.mehta@pinc.co.in	91-22-6618 6333
Chandani Bhatia		chandani.bhatia@pinc.co.in	91-22-6618 6324
Hasmukh D. Prajapati		hasmukhp@pinc.co.in	91-22-6618 6325
Kamlesh Purohit		kamlesh.purohit@pinc.co.in	91-22-6618 6357

SINGAPORE DESK

Amul Shah		amul.shah@sg.pinc.co.in	65-6327 0626
-----------	--	-------------------------	--------------

DIRECTORS

Gaurang Gandhi		gaurangg@pinc.co.in	91-22-6618 6400
Hemang Gandhi		hemangg@pinc.co.in	91-22-6618 6400
Ketan Gandhi		ketang@pinc.co.in	91-22-6618 6400

COMPLIANCE

Rakesh Bhatia	Head Compliance	rakeshb@pinc.co.in	91-22-6618 6400
---------------	-----------------	--------------------	-----------------

PINC bright thinking

Infinity.com

Financial Securities Ltd

SMALL WORLD, INFINITE OPPORTUNITIES

Member : Bombay Stock Exchange & National Stock Exchange of India Ltd. : Sebi Reg No: INB 010989331. Clearing No : 211
1216, Maker Chambers V, Nariman Point, Mumbai - 400 021; Tel.: 91-22-66186633/6400 Fax : 91-22-22049195

Disclaimer: This document has been prepared by the Research Desk of M/s Infinity.com Financial Securities Ltd. (PINC) and is meant for use of the recipient only and is not for public circulation. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors

The information contained herein is obtained and collated from sources believed reliable and PINC has not independently verified all the information given in this document. Accordingly, no representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document.

The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The opinion expressed or estimates made are as per the best judgement as applicable at that point of time and PINC reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval

PINC, its affiliates, their directors, employees and their dependant family members may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document

This report has been prepared on the basis of information, which is already available in publicly accessible media or developed through analysis of PINC. The views expressed are those of analyst and the PINC may or may not subscribe to all the views expressed therein

This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. Neither this document nor any copy of it may be taken or transmitted into the United State (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. The distribution of this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions

Neither PINC, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information.

Copyright in this document vests exclusively with PINC and this document is not to be reported or circulated or copied or made available to others.

Our reports are also available on Reuters, Thomson Publishers and Bloomberg PINV <GO>